“36th Annual Pittsburgh Schizophrenia Conference”
(MD44)

November 15, 2019

Sheraton Station Square
Pittsburgh, PA

7:30 am – Registration
8:30 AM to 4:45 PM - Conference

Course Director:

KN Roy Chengappa, MD

Recovery and Wellness: The Journey Starts Here
A Joint Effort Sponsored by Community Care Behavioral Health and
UPMC Western Psychiatric Hospital
“36th Annual Pittsburgh Schizophrenia Conference”
Sheraton Station Square
300 W. Station Square Dr.
Pittsburgh, PA 15219

November 15, 2019

Introduction

The Pittsburgh Schizophrenia Conference is an annual meeting at which the advances in schizophrenia research are reviewed by experts in the field. This year’s meeting will cover early identification and management of first episode psychoses based on knowledge obtained and disseminated from a NIMH funded trial. Attendees will learn and review immune-inflammatory mechanisms that play a role in subgroups of persons with schizophrenia, especially gluten sensitivity and ongoing work to remediate this sensitivity. Participants will hear about transcranial magnetic stimulation (TMS) and its potential use in schizophrenia. From a case example, attendees will learn about clarifying diagnosis and optimizing medications in persons with mental illness in a residential facility. Finally, attendees will hear from people with serious mental illness who will share their stories of working as Peer Specialists and of using music to help support their recovery.

Who Should Attend

The conference is designed to disseminate the latest clinical and research findings to a wide audience: psychiatrists and other mental health clinicians, including nurses, social workers, psychologists, service coordinators, researchers, patients and their relatives, mental health policy administrators and others who intend to keep current regarding treatment research in schizophrenia.

Learning Objectives

At the completion of the program, participants should be able to:
1. Recognize the essential elements of coordinated specialty care early in the course of schizophrenia.
2. Recognize the concept of the duration of untreated psychoses and steps taken to reduce the duration.
3. Discuss ongoing research to characterize a subgroup of schizophrenia patients with immune response and inflammation to gluten.
4. Identify potential pathophysiologic mechanisms related to an immune response to gluten.
5. Explain ongoing work for personalizing treatment in this subgroup of schizophrenia with potential gluten sensitivity.
6. Recognize the basic mechanisms of non-invasive brain activity modulation with TMS.
7. Review the safety profile of TMS treatments.
8. Review studies investigating the use of TMS in patients with schizophrenia and psychotic disorders.
9. Discuss if a step down longer stay residential placement provides value for clarifying the diagnosis and revisit the treatment approach to persons with serious mental illness.
Gerard E. Hogarty Excellence in Schizophrenia Research Memorial Award Winner

John M. Kane, MD
Senior Vice President for Behavioral Health Services
Northwell Health, New Hyde Park, NY
Professor and Chairman
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
The Zucker Hillside Hospital, Glen Oaks, NY

John M. Kane, MD, is Senior Vice President for Behavioral Health Services at Northwell Health in New Hyde Park, New York. He is Professor and Chairman of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He also serves as Chairman of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York. Dr. Kane received a BA from Cornell University and earned his medical degree from New York University School of Medicine. He completed his residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Kane is the recipient of many awards, including: the Lieber Prize; The APA’s Kempf Award, the Gralnick Award and Foundations Prize; the New York State Office of Mental Health Lifetime Achievement Award; and The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatric Research Society and the Schizophrenia International Research Society. Dr. Kane has been the principal investigator for research projects focusing on schizophrenia psychobiology, treatment and recovery, as well as improving the quality and cost of care. He is the author of 600 peer-reviewed papers and serves on the editorial boards of numerous journals.

Gerard E. Hogarty Excellence in Schizophrenia Research Memorial Lecture:
“Lessons Learned From RAISE-ETP: Where Do We Go from Here?”

The early identification and management of first episode psychosis remains an enormous challenge, yet its success can play a pivotal role in subsequent outcome. The NIMH-funded RAISE-ETP program demonstrated a number of advantages for coordinated specialty care (CSC) in comparison to usual community care. Specifically, participants receiving coordinated specialty care did better on quality of life, symptoms, retention in treatment and return to work or school. At the same time, the median duration of untreated psychosis (DUP) in this sample from 21 different states across the U.S. was 74 weeks, with 68% of participants having a DUP of greater than six months. Longer DUP was associated with less benefit from CSC.

This presentation will review some of the factors contributing to DUP and some approaches to potentially reducing it-involving social media and the Internet. In addition, despite CSC, 34% of these first episode patients were hospitalized within the next two years in comparison to 37% in the control condition. Not surprisingly, attitudes towards medication-taking was one of the predictors of hospitalization. This presentation will also discuss the adherence challenge and recent efforts to increase the utilization of long-acting formulations of antipsychotic medications. Much of this work links directly back to the enormous contributions of Gerard Hogarty.

By the completion of this session, participants should be able to:
1. Recognize the basics of coordinated specialty care in early phase schizophrenia
2. Discuss recent findings from controlled trials of coordinated specialty care
3. Discuss the impact of the duration of untreated psychosis and describe different steps being taken to reduce it
Course Director

K.N. Roy Chengappa, MD
Professor of Psychiatry
University of Pittsburgh School of Medicine
Chief, Comprehensive Recovery Services
UPMC Western Psychiatric Hospital
Pittsburgh, PA

Gerard E. Hogarty Excellence in Schizophrenia Research Memorial Award Winner

John M. Kane, MD
Senior Vice President for Behavioral Health Services
Northwell Health
New Hyde Park, NY
Professor and Chairman
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
The Zucker Hillside Hospital
Glen Oaks, NY

Faculty

Steven D. Forman MD, PhD
Staff Physician & Research Investigator
Program Chief, Transcranial Magnetic Stimulation Clinic
VA Pittsburgh Healthcare System
Assistant Professor of Psychiatry
University of Pittsburgh School of Medicine
Pittsburgh, PA

Bernice Hayes, CPS
Senior Peer Specialist
UPMC Western Psychiatric Hospital
Pittsburgh, PA

Deanna L. Kelly, PharmD., BCPP
Professor of Psychiatry
Director, Treatment Research Program (TRP)
Maryland Psychiatric Research Center (MPRC)
University of Maryland School of Medicine

Shaun M. Eack, PhD
David E. Epperson Professor of Social Work
Professor of Psychiatry School of Social Work and Department of Psychiatry
University of Pittsburgh
UPMC Western Psychiatric Hospital
Pittsburgh, PA

Susan Hogarty, RN, MSN
Psychiatric Clinical Nurse Specialist
Research Program Administrator
ASCEND Program
Comprehensive Recovery Services
UPMC Western Psychiatric Hospital
Pittsburgh, PA
Stacy Martin, LSW
Behavioral Health Counselor
UPMC Western Psychiatric Hospital
Pittsburgh, PA

Vernon Ian Nathaniel, MD
Assistant Professor of Psychiatry
University of Pittsburgh School of Medicine
Medical Director and Attending Psychiatrist
Community Treatment Team-Transitional Age
UPMC Western Psychiatric Hospital
Pittsburgh, PA

Susan Brown Padilla, CPS
Senior Peer Specialist
UPMC Western Psychiatric Hospital
Pittsburgh, PA

Susan Wolfe, MA, LPC
Program Director Community Treatment Team (CTT)
UPMC Western Psychiatric Hospital
Pittsburgh, PA

Panel Moderator

Flavio Chamis
Composer, Conductor, Educator, Music Consultant and Producer

The University of Pittsburgh is an affirmative action, equal opportunity institution.
All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:

Steven D. Forman, MD, PhD  Stockholder: Neurocrine

John M. Kane, MD  Grant/Research Support: Otsuka, Lundbeck, Janssen

Consultant:
Forum, Allergan, Alkermes, Eli Lilly, Genentech, Lundbeck, Intracellular Therapies, Janssen, Johnson & Johnson, Neurocrine, Otsuka, Pierre Fabre, Merck, Reviva, Roche, Sunovion, Takeda, Teva

Stockholder: Vanguard Research Group, LB Pharmaceuticals

Other: Advisory Board: Alkermes, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Takeda, Teva, Pierre Fabre

Deanna L. Kelly, PharmD, BCPP  Consultant: Alkermes, HLS Therapeutics

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Schedule

7:30 am  Registration and Continental Breakfast

8:30 am  Introduction and Background  
*K.N. Roy Chengappa, MD*

8:45-10:15 am  The Gerard E. Hogarty Excellence in Schizophrenia Research Memorial Award

8:45 to 9:00  Review of Dr. Kane’s work  
*Shaun M. Eack, PhD*

    Presentation of plaque to John M. Kane, MD  
*Susan Hogarty, RN, MSN*

9:00-10:15 am  Gerard E. Hogarty Excellence in Schizophrenia Research Memorial Lecture

    Lessons Learned from RAISE-ETP: Where Do We Go from Here?  
*John M. Kane, MD*

    9:00 to 10:00  Presentation  
    10:00 to 10:15  Q&A session

10:15-10:30 am  Break

10:30-11:45 am  Gluten and Schizophrenia: New Target and Precision Medicine?  
*Deanna L. Kelly, Pharm.D., BCPP*

    10:30-11:30  Presentation  
    11:30-11:45  Q&A session

11:45-1:00 pm  Lunch (on own)

1:00-2:15 pm  Transcranial Magnetic Stimulation (TMS) in Schizophrenia and Psychosis – 2019 Update  
*Steven D. Forman MD, PhD*

    1:00-2:00  Presentation  
    2:00-2:15  Q&A session

2:15 – 3:30 pm  Deprescription and Optimization of Medications  
Vernon Nathaniel, MD  
*Susan Wolfe, MA, LPC, Program Director CTT*
*Stacy Martin, LSW, Behavioral Health Counselor*

    2:15-3:15  Presentation  
    3:15-3:30  Q&A session

3:30 - 3:40 pm  Break

3:40 – 4:40 pm  Peer Specialists: Sharing and Working  
*Susan Brown Padilla, CPS, Senior Peer Specialist*
*Bernice Hayes, CPS, Senior Peer Specialist*
*Flavio Chamis, Music Director and peer musicians*

4:40-4:50  Closing Remarks and Adjournment  
*K.N. Roy Chengappa, MD*
ACKNOWLEDGEMENTS

We gratefully acknowledge Community Care Behavioral Health Organization, an affiliate of the UPMC Health Plan, for their continued, generous support for this program.

We would also like to acknowledge the following commercial exhibitors for their financial support for this program:

JANSSEN NEUROSCIENCE
OTSUKA AMERICA PHARMACEUTICALS
SUNOVIAN PHARMACEUTICALS
TEVA PHARMACEUTICAL, INC.
US ARMY HEALTHCARE TEAM
Continuing Education Credit
Physicians

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this live activity for a maximum of 6.5 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Psychologists
UPMC Western Psychiatric Hospital is approved by the American Psychological Association to offer continuing education for psychologists. UPMC Western Psychiatric Hospital maintains responsibility for this program and its content. This program is being offered for 6.25 continuing education credits.

Certified Alcohol and Drug Counselors/Certified Co-Occurring Disorders Professionals (CADC/CCDP):
The Office of Education and Regional Programming, UPMC Western Psychiatric Hospital is certified by the Pennsylvania Certification Board (PCB) to provide Certified Alcohol and Drug Counselor (CADC) and Certified Co-Occurring Disorders Professional (CCDP) continuing education credits. This program is being offered for 6.25 continuing education credits.

Counselors
UPMC Western Psychiatric Hospital has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5059. Programs that do not qualify for NBCC credit are clearly identified. UPMC Western Psychiatric Hospital is solely responsible for all aspects of this program. This program is being offered for 6.25 continuing education hours.

Licensed/Clinical Social Workers, Licensed Professional Counselors, Licensed Marriage and Family Therapists: LSW/LCSW/LPC/LMFT
This program is offered for 6.0 hours of social work continuing education through co-sponsorship of the University of Pittsburgh’s School of Social Work, a Council on Social Work Education-accredited school and, therefore, a PA pre-approved provider of social work continuing education. These credit hours satisfy requirements for LSW/LCSW, LPC and LMFT biennial license renewal. For information on social work continuing education call (412) 624-3711.

Other Healthcare Professionals
Nurses and other health care professionals are awarded .625 Continuing Education Units (CEU's). One CEU is equal to 10 contact hours. **Nurses:** For attending this program you will receive a Certificate of Attendance confirming 6.25 units of continuing education. These units may be considered eligible for completing the 30 hours of continuing education required for biennial nursing re-licensure in Pennsylvania. **Peer Specialists:** This program fulfills requirements for Certified Peer Specialist continuing education.